Precision Medicine in Neurodegenerative Disorders: Part I
Gespeichert in:
| Beteilige Person: | |
|---|---|
| Format: | Buch |
| Sprache: | Englisch |
| Veröffentlicht: |
San Diego
Elsevier
2023
|
| Schriftenreihe: | Handbook of clinical neurology
volume 192, 3rd series |
| Abstract: | Intro -- Precision Medicine in Neurodegenerative Disorders, Part I -- Copyright -- Available titles -- Foreword -- In Memoriam-Michael Parkinson -- Preface -- Contributors -- Contents -- Part 1: Conceptual framework -- Chapter 1: The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension -- Introduction -- Lessons from other fields -- Precision Medicine in the Fields of Oncology vs Neurodegeneration -- One Disease-Many Diseases Tension -- Why have we failed in disease modification? -- Disease heterogeneity -- Clinical heterogeneity -- Clinical subtypes -- Data-driven subtypes -- Challenges related to both approaches -- The ''brain-first''/''body-first'' hypothesis -- Genetic heterogeneity -- Environmental factors contributing to heterogeneity -- Pathologic heterogeneity -- Other concomitant proteinopathies/concurrent factors -- Pathogenic heterogeneity -- Heterogeneity and the One Disease-Many Diseases Tension -- Requirements for precision medicine -- Biomarkers -- Diagnostic accuracy -- The concept of prodromal stages of neurodegenerative diseases -- Moving From Heterogeneity to Precision Medicine and Successful DMT -- Conclusion -- References -- Chapter 2: Models of precision medicine for neurodegeneration -- From the Clinicopathologic Model to Individualized Biological Subtyping -- Is the Model for Symptomatic Treatments Also Helpful for Precision Medicine? -- The Big Picture -- Logistical Implications of the Clinicopathologic Model of Disease -- The false allure of a perfect trial -- If PD is not one disease, why dont we strategize as if we mean it? -- The epidemiology-therapy disconnect -- Toxic pathology? -- When do we reject a hypothesis? -- ''Lessons from failures'' -- Why Is There Resistance to Change Away From the Clinicopathology Model?. |
| Umfang: | xviii, 269 pages |
| ISBN: | 9780323855389 |
Internformat
MARC
| LEADER | 00000nam a22000001cb4500 | ||
|---|---|---|---|
| 001 | BV049090174 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t| | ||
| 008 | 230804s2023 xx |||| 00||| eng d | ||
| 020 | |a 9780323855389 |9 9780323855389 | ||
| 035 | |a (OCoLC)1401188727 | ||
| 035 | |a (DE-599)BVBBV049090174 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 | ||
| 100 | 1 | |a Espay, Alberto J. |d ca. 20./21. Jh. |e Verfasser |0 (DE-588)1081843268 |4 aut | |
| 245 | 1 | 0 | |a Precision Medicine in Neurodegenerative Disorders |b Part I |
| 264 | 1 | |a San Diego |b Elsevier |c 2023 | |
| 300 | |a xviii, 269 pages | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Handbook of clinical neurology |v volume 192, 3rd series | |
| 520 | 3 | |a Intro -- Precision Medicine in Neurodegenerative Disorders, Part I -- Copyright -- Available titles -- Foreword -- In Memoriam-Michael Parkinson -- Preface -- Contributors -- Contents -- Part 1: Conceptual framework -- Chapter 1: The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension -- Introduction -- Lessons from other fields -- Precision Medicine in the Fields of Oncology vs Neurodegeneration -- One Disease-Many Diseases Tension -- Why have we failed in disease modification? -- Disease heterogeneity -- Clinical heterogeneity -- Clinical subtypes -- Data-driven subtypes -- Challenges related to both approaches -- The ''brain-first''/''body-first'' hypothesis -- Genetic heterogeneity -- Environmental factors contributing to heterogeneity -- Pathologic heterogeneity -- Other concomitant proteinopathies/concurrent factors -- Pathogenic heterogeneity -- Heterogeneity and the One Disease-Many Diseases Tension -- Requirements for precision medicine -- Biomarkers -- Diagnostic accuracy -- The concept of prodromal stages of neurodegenerative diseases -- Moving From Heterogeneity to Precision Medicine and Successful DMT -- Conclusion -- References -- Chapter 2: Models of precision medicine for neurodegeneration -- From the Clinicopathologic Model to Individualized Biological Subtyping -- Is the Model for Symptomatic Treatments Also Helpful for Precision Medicine? -- The Big Picture -- Logistical Implications of the Clinicopathologic Model of Disease -- The false allure of a perfect trial -- If PD is not one disease, why dont we strategize as if we mean it? -- The epidemiology-therapy disconnect -- Toxic pathology? -- When do we reject a hypothesis? -- ''Lessons from failures'' -- Why Is There Resistance to Change Away From the Clinicopathology Model?. | |
| 776 | 0 | 8 | |i Erscheint auch als |n Online-Ausgabe |z 978-0-323-90064-5 |
| 830 | 0 | |a Handbook of clinical neurology |v volume 192, 3rd series |w (DE-604)BV000069154 |9 192 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-034351911 | |
Datensatz im Suchindex
| _version_ | 1818990826414407680 |
|---|---|
| any_adam_object | |
| author | Espay, Alberto J. ca. 20./21. Jh |
| author_GND | (DE-588)1081843268 |
| author_facet | Espay, Alberto J. ca. 20./21. Jh |
| author_role | aut |
| author_sort | Espay, Alberto J. ca. 20./21. Jh |
| author_variant | a j e aj aje |
| building | Verbundindex |
| bvnumber | BV049090174 |
| ctrlnum | (OCoLC)1401188727 (DE-599)BVBBV049090174 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02823nam a22003011cb4500</leader><controlfield tag="001">BV049090174</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">230804s2023 xx |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780323855389</subfield><subfield code="9">9780323855389</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1401188727</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV049090174</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Espay, Alberto J.</subfield><subfield code="d">ca. 20./21. Jh.</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)1081843268</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Precision Medicine in Neurodegenerative Disorders</subfield><subfield code="b">Part I</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">San Diego</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">xviii, 269 pages</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Handbook of clinical neurology</subfield><subfield code="v">volume 192, 3rd series</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Intro -- Precision Medicine in Neurodegenerative Disorders, Part I -- Copyright -- Available titles -- Foreword -- In Memoriam-Michael Parkinson -- Preface -- Contributors -- Contents -- Part 1: Conceptual framework -- Chapter 1: The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension -- Introduction -- Lessons from other fields -- Precision Medicine in the Fields of Oncology vs Neurodegeneration -- One Disease-Many Diseases Tension -- Why have we failed in disease modification? -- Disease heterogeneity -- Clinical heterogeneity -- Clinical subtypes -- Data-driven subtypes -- Challenges related to both approaches -- The ''brain-first''/''body-first'' hypothesis -- Genetic heterogeneity -- Environmental factors contributing to heterogeneity -- Pathologic heterogeneity -- Other concomitant proteinopathies/concurrent factors -- Pathogenic heterogeneity -- Heterogeneity and the One Disease-Many Diseases Tension -- Requirements for precision medicine -- Biomarkers -- Diagnostic accuracy -- The concept of prodromal stages of neurodegenerative diseases -- Moving From Heterogeneity to Precision Medicine and Successful DMT -- Conclusion -- References -- Chapter 2: Models of precision medicine for neurodegeneration -- From the Clinicopathologic Model to Individualized Biological Subtyping -- Is the Model for Symptomatic Treatments Also Helpful for Precision Medicine? -- The Big Picture -- Logistical Implications of the Clinicopathologic Model of Disease -- The false allure of a perfect trial -- If PD is not one disease, why dont we strategize as if we mean it? -- The epidemiology-therapy disconnect -- Toxic pathology? -- When do we reject a hypothesis? -- ''Lessons from failures'' -- Why Is There Resistance to Change Away From the Clinicopathology Model?.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Online-Ausgabe</subfield><subfield code="z">978-0-323-90064-5</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Handbook of clinical neurology</subfield><subfield code="v">volume 192, 3rd series</subfield><subfield code="w">(DE-604)BV000069154</subfield><subfield code="9">192</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-034351911</subfield></datafield></record></collection> |
| id | DE-604.BV049090174 |
| illustrated | Not Illustrated |
| indexdate | 2024-12-20T20:00:32Z |
| institution | BVB |
| isbn | 9780323855389 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-034351911 |
| oclc_num | 1401188727 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | xviii, 269 pages |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | Elsevier |
| record_format | marc |
| series | Handbook of clinical neurology |
| series2 | Handbook of clinical neurology |
| spelling | Espay, Alberto J. ca. 20./21. Jh. Verfasser (DE-588)1081843268 aut Precision Medicine in Neurodegenerative Disorders Part I San Diego Elsevier 2023 xviii, 269 pages txt rdacontent n rdamedia nc rdacarrier Handbook of clinical neurology volume 192, 3rd series Intro -- Precision Medicine in Neurodegenerative Disorders, Part I -- Copyright -- Available titles -- Foreword -- In Memoriam-Michael Parkinson -- Preface -- Contributors -- Contents -- Part 1: Conceptual framework -- Chapter 1: The definition of precision medicine in neurodegenerative disorders and the one disease-many diseases tension -- Introduction -- Lessons from other fields -- Precision Medicine in the Fields of Oncology vs Neurodegeneration -- One Disease-Many Diseases Tension -- Why have we failed in disease modification? -- Disease heterogeneity -- Clinical heterogeneity -- Clinical subtypes -- Data-driven subtypes -- Challenges related to both approaches -- The ''brain-first''/''body-first'' hypothesis -- Genetic heterogeneity -- Environmental factors contributing to heterogeneity -- Pathologic heterogeneity -- Other concomitant proteinopathies/concurrent factors -- Pathogenic heterogeneity -- Heterogeneity and the One Disease-Many Diseases Tension -- Requirements for precision medicine -- Biomarkers -- Diagnostic accuracy -- The concept of prodromal stages of neurodegenerative diseases -- Moving From Heterogeneity to Precision Medicine and Successful DMT -- Conclusion -- References -- Chapter 2: Models of precision medicine for neurodegeneration -- From the Clinicopathologic Model to Individualized Biological Subtyping -- Is the Model for Symptomatic Treatments Also Helpful for Precision Medicine? -- The Big Picture -- Logistical Implications of the Clinicopathologic Model of Disease -- The false allure of a perfect trial -- If PD is not one disease, why dont we strategize as if we mean it? -- The epidemiology-therapy disconnect -- Toxic pathology? -- When do we reject a hypothesis? -- ''Lessons from failures'' -- Why Is There Resistance to Change Away From the Clinicopathology Model?. Erscheint auch als Online-Ausgabe 978-0-323-90064-5 Handbook of clinical neurology volume 192, 3rd series (DE-604)BV000069154 192 |
| spellingShingle | Espay, Alberto J. ca. 20./21. Jh Precision Medicine in Neurodegenerative Disorders Part I Handbook of clinical neurology |
| title | Precision Medicine in Neurodegenerative Disorders Part I |
| title_auth | Precision Medicine in Neurodegenerative Disorders Part I |
| title_exact_search | Precision Medicine in Neurodegenerative Disorders Part I |
| title_full | Precision Medicine in Neurodegenerative Disorders Part I |
| title_fullStr | Precision Medicine in Neurodegenerative Disorders Part I |
| title_full_unstemmed | Precision Medicine in Neurodegenerative Disorders Part I |
| title_short | Precision Medicine in Neurodegenerative Disorders |
| title_sort | precision medicine in neurodegenerative disorders part i |
| title_sub | Part I |
| volume_link | (DE-604)BV000069154 |
| work_keys_str_mv | AT espayalbertoj precisionmedicineinneurodegenerativedisordersparti |